The Rationale for Targeted Therapies and Stereotactic Radiosurgery in the Treatment of Brain Metastases. (13th January 2016)

• Record Type: Journal Article
• Authors: Moraes, Fabio Ynoe; Taunk, Neil K.; Marta, Gustavo Nader; Suh, John H.; Yamada, Yoshiya
• Is Part Of: Oncologist. Volume 21:Number 2(2016)
• Page Start: 244
• Page End: 251
• Publication Date: 2016-01-13
• Subjects: Targeted therapy -- Stereotactic radiosurgery -- Brain metastasis; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2015-0293
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract: Brain metastases are the most common intracranial malignancy. Many approaches, including radiation therapy, surgery, and cytotoxic chemotherapy, have been used to treat patients with brain metastases depending on the patient's disease burden and symptoms. However, stereotactic surgery (SRS) has revolutionized local treatment of brain metastases. Likewise, targeted therapies, including small-molecule inhibitors and monoclonal antibodies that target cancer cell metabolism or angiogenesis, have transformed managing systemic disease. Prospective data on combining these treatments for synergistic effect are limited, but early data show favorable safety and efficacy profiles. The combination of SRS and targeted therapy will further individualize treatment, potentially obviating the need for cytotoxic chemotherapy or whole-brain radiation. There is a great need to pursue research into these exciting modalities and novel combinations to further improve the treatment of patients with brain metastases. This article discusses reported and ongoing clinical trials assessing the safety and efficacy of targeted therapy during SRS. Abstract : Stereotactic surgery (SRS) has revolutionized local treatment of brain metastases. Targeted therapies, including small-molecule inhibitors and monoclonal antibodies that target cancer cell metabolism or angiogenesis, have transformed managing systemic disease. This article discusses reported and ongoing clinical trials assessing the safety and efficacy of targeted therapy during SRS.